Ermanno Greco
Ermanno Greco has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Spinella
Eurofins Genoma Group, Molecular Genetics Laboratories, Rome, Italy
4 shared publications Alessandra Ruberti
Department of Reproductive Medicine, Rome, Italy
3 shared publications- Manuel Viotti
Zouves Foundation for Reproductive Medicine, Foster City, CA
3 shared publications Anil Biricik
Eurofins Genoma Group, Molecular Genetics Laboratories , Rome, Italy
2 shared publications- Antonio La Marca
University of Modena and Reggio Emilia
2 shared publications - Francesco Fiorentino
Genoma, Molecular Genetics Laboratory, Rome, Italy
2 shared publications
Latest Publications
- 3 November 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 143-153
Beyond aneuploidy: embryo morphology, maternal age, and miscarriage dynamics in PGT-A selected single embryo transfer
Purpose The study addresses whether maternal age, embryo morphology, and blastocyst developmental timing interact to influence pregnancy success rates in PGT-A selected single embryo transfer (PGT-A sSET), confirmed as euploid or exhibiting low-level (≤ 40%) mosaicism; and whether the chromosomal health of the embryo mitigates all aspects of age-related fertility decline. Methods We retrospectively analyzed 822 frozen PGT-A sSET cycles performed at Villa Mafalda private clinic (July 2020–December 2024): 771 autologous and 51 donor-oocyte transfers. Outcomes were ongoing pregnancy/live birth, implantation, and miscarriage rates, evaluated in relation to maternal age, considered both as categorical brackets (≤ 34, 35–38, 39–41, ≥ 42 years) and as a continuous variable. Results Women ≥ 42 yr showed lower ongoing-pregnancy and live-birth rates, poorer morphology, delayed blastocyst expansion than younger groups (all p < 0.05); no differences emerged among the younger brackets. In the multivariable logistic‐regression model, embryo morphology emerged as the strongest determinant of success: Good‐quality embryos showed 2.8-fold increase in ongoing pregnancy/live‐birth odds (95% CI 1.61–4.92; p = 0.0003) and Excellent-quality embryos 4.6-fold increase (95% CI 2.63–8.05; p < 0.0001) versus Poor-quality category. Finally, each additional year of maternal age increased miscarriage risk by 11% (RR 1.11, 95% CI 1.03–1.19; p = 0.005). Conclusions Our results reinforce that, even among chromosomally normal blastocysts, morphological quality predominates over maternal age and blastocyst developmental timing in predicting pregnancy success. Maternal age exerts its effect largely by compromising embryo competence—beyond simply increasing aneuploidy rates—pointing to additional, age‐related alterations in embryonic physiology.
- 3 November 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 143-153
Beyond aneuploidy: embryo morphology, maternal age, and miscarriage dynamics in PGT-A selected single embryo transfer
Purpose The study addresses whether maternal age, embryo morphology, and blastocyst developmental timing interact to influence pregnancy success rates in PGT-A selected single embryo transfer (PGT-A sSET), confirmed as euploid or exhibiting low-level (≤ 40%) mosaicism; and whether the chromosomal health of the embryo mitigates all aspects of age-related fertility decline. Methods We retrospectively analyzed 822 frozen PGT-A sSET cycles performed at Villa Mafalda private clinic (July 2020–December 2024): 771 autologous and 51 donor-oocyte transfers. Outcomes were ongoing pregnancy/live birth, implantation, and miscarriage rates, evaluated in relation to maternal age, considered both as categorical brackets (≤ 34, 35–38, 39–41, ≥ 42 years) and as a continuous variable. Results Women ≥ 42 yr showed lower ongoing-pregnancy and live-birth rates, poorer morphology, delayed blastocyst expansion than younger groups (all p < 0.05); no differences emerged among the younger brackets. In the multivariable logistic‐regression model, embryo morphology emerged as the strongest determinant of success: Good‐quality embryos showed 2.8-fold increase in ongoing pregnancy/live‐birth odds (95% CI 1.61–4.92; p = 0.0003) and Excellent-quality embryos 4.6-fold increase (95% CI 2.63–8.05; p < 0.0001) versus Poor-quality category. Finally, each additional year of maternal age increased miscarriage risk by 11% (RR 1.11, 95% CI 1.03–1.19; p = 0.005). Conclusions Our results reinforce that, even among chromosomally normal blastocysts, morphological quality predominates over maternal age and blastocyst developmental timing in predicting pregnancy success. Maternal age exerts its effect largely by compromising embryo competence—beyond simply increasing aneuploidy rates—pointing to additional, age‐related alterations in embryonic physiology.
- 20 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (1) , 125-138
Time-lapse analysis of embryos classified as euploid, mosaic, and aneuploid after embryonic trophectoderm biopsy
Purpose Analyze morphokinetic, morphology, and KIDscore™Day5 in different PGT-A classes, focusing on putative mosaicism level and type. Methods The single-center retrospective study analyzed 832 embryoscope-cultured blastocysts from cycles with at least one putative mosaic, conducted from 2020 to 2022. A P-value < 0.05 was considered statistically significant. Results Putative mosaic embryos were significantly delayed compared to euploid in tPNF, t2, t4, t7, and t8 but significantly faster than aneuploid in tPNF, t2, t3, t4, t5, tSC, tM, tSB, and tB. Regarding the level, low-putative mosaic embryos (< 50%) showed significantly earlier tSC, tM, tSB, and tB compared to aneuploid, whereas high-putative mosaic embryos exhibited significantly earlier tSB and tB. Concerning the type of putative mosaicism, segmental aneuploidies reached significantly earlier t8, tM, and tB than complex aneuploidies. The study also investigated the usefulness of KIDscore™Day5 for embryo selection as an additional tool to PGT-A. A significant decrease in KIDscore™Day5 was observed from euploid to low-putative mosaic, from high-putative mosaic to aneuploid, and between segmental and complex-putative mosaic. The observed differences in KIDscore™Day5 were partially confirmed by transfer results: euploid blastocysts showed the most favorable clinical outcomes compared to low- and high-putative mosaics. Additionally, both euploid and segmental putative mosaic embryos exhibited the best clinical results compared to whole chromosome and complex putative mosaic. Moreover, within the same PGT-A class, embryos with the lowest KIDscore™Day5 values had significantly lower clinical results. Conclusions The data highlight that morphology, morphokinetics, and chromosome content in trophectoderm biopsy are closely related, and the KIDscore™Day5 algorithm reflects this interplay.
- 20 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (1) , 125-138
Time-lapse analysis of embryos classified as euploid, mosaic, and aneuploid after embryonic trophectoderm biopsy
Purpose Analyze morphokinetic, morphology, and KIDscore™Day5 in different PGT-A classes, focusing on putative mosaicism level and type. Methods The single-center retrospective study analyzed 832 embryoscope-cultured blastocysts from cycles with at least one putative mosaic, conducted from 2020 to 2022. A P-value < 0.05 was considered statistically significant. Results Putative mosaic embryos were significantly delayed compared to euploid in tPNF, t2, t4, t7, and t8 but significantly faster than aneuploid in tPNF, t2, t3, t4, t5, tSC, tM, tSB, and tB. Regarding the level, low-putative mosaic embryos (< 50%) showed significantly earlier tSC, tM, tSB, and tB compared to aneuploid, whereas high-putative mosaic embryos exhibited significantly earlier tSB and tB. Concerning the type of putative mosaicism, segmental aneuploidies reached significantly earlier t8, tM, and tB than complex aneuploidies. The study also investigated the usefulness of KIDscore™Day5 for embryo selection as an additional tool to PGT-A. A significant decrease in KIDscore™Day5 was observed from euploid to low-putative mosaic, from high-putative mosaic to aneuploid, and between segmental and complex-putative mosaic. The observed differences in KIDscore™Day5 were partially confirmed by transfer results: euploid blastocysts showed the most favorable clinical outcomes compared to low- and high-putative mosaics. Additionally, both euploid and segmental putative mosaic embryos exhibited the best clinical results compared to whole chromosome and complex putative mosaic. Moreover, within the same PGT-A class, embryos with the lowest KIDscore™Day5 values had significantly lower clinical results. Conclusions The data highlight that morphology, morphokinetics, and chromosome content in trophectoderm biopsy are closely related, and the KIDscore™Day5 algorithm reflects this interplay.
- 20 July 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (9) , 1784-1788
Predicting the total number of retrieved oocytes following double ovarian stimulation (DuoStim)
Can anti-Müllerian hormone (AMH) help predict how many oocytes will be retrieved following double stimulation (DuoStim)? A simple clinical tool can use serum AMH values to predict ovarian response following DuoStim in IVF cycles. The knowledge that multiple follicular waves arise during a single ovarian cycle has led to the introduction of unconventional ovarian stimulation protocols. The DuoStim protocol involves two successive ovarian stimulations performed during a single ovarian cycle and has been proposed as an approach for patients with poor ovarian response and for medical fertility preservation. As AMH has been used as a marker of ovarian reserve and stimulation response, the current study aimed to investigate the diagnostic performance of AMH in predicting the number of retrieved oocytes following DuoStim. This is a retrospective observational study involving 116 patients who received IVF treatment from January 2021 to September 2022. The study was conducted at a private IVF centre. Only patients who had their AMH measured prior to treatment and had complete patient records regarding their clinical and IVF/ICSI cycle characteristics were included. The primary outcome was the correlation between AMH values and the number of oocytes retrieved following DuoStim. Parametric and non-parametric tests were used to compare baseline characteristics and outcomes. Spearman’s R was used to analyse correlations between variables, while the C statistic was used to calculate the diagnostic performance of AMH. AMH levels were significantly correlated with the total number of oocytes retrieved after the DuoStim (R 0.61; CI 0.44–0.70; P < 0.0001). The difference in the total number of oocytes retrieved between the first (median 4 oocytes, interquartile range (IQR) 2–6) and second (median 6 oocytes, IQR 3.2–8) stimulation was statistically significant (P < 0.0001). However, there was no significant difference in the number of mature oocytes that were retrieved (median of 3 and 4 in the first and second stimulations, respectively). After the first stimulation, 68% of patients had at least one blastocyst available, while after the second stimulation, 74% did (NS). Based on linear regression, each 0.25 ng/ml increase in basal AMH corresponds to one additional oocyte recovered at the end of both stimulations (R2: 0.32, P < 0.0001). The results are limited owing to the observational nature of the study and the number of participants. Counselling infertile couples regarding the intermediate outcome of IVF (i.e. number of retrieved oocytes) is one of the most demanding tasks that clinicians face. To our knowledge, this is the first study that provides an easy-to-use clinical tool that enables the quantitative prediction of ovarian response following DuoStim, based on serum AMH values. No external funding was obtained for this study. The authors declare no conflicts of interest. N/A.
- 20 July 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (9) , 1784-1788
Predicting the total number of retrieved oocytes following double ovarian stimulation (DuoStim)
Can anti-Müllerian hormone (AMH) help predict how many oocytes will be retrieved following double stimulation (DuoStim)? A simple clinical tool can use serum AMH values to predict ovarian response following DuoStim in IVF cycles. The knowledge that multiple follicular waves arise during a single ovarian cycle has led to the introduction of unconventional ovarian stimulation protocols. The DuoStim protocol involves two successive ovarian stimulations performed during a single ovarian cycle and has been proposed as an approach for patients with poor ovarian response and for medical fertility preservation. As AMH has been used as a marker of ovarian reserve and stimulation response, the current study aimed to investigate the diagnostic performance of AMH in predicting the number of retrieved oocytes following DuoStim. This is a retrospective observational study involving 116 patients who received IVF treatment from January 2021 to September 2022. The study was conducted at a private IVF centre. Only patients who had their AMH measured prior to treatment and had complete patient records regarding their clinical and IVF/ICSI cycle characteristics were included. The primary outcome was the correlation between AMH values and the number of oocytes retrieved following DuoStim. Parametric and non-parametric tests were used to compare baseline characteristics and outcomes. Spearman’s R was used to analyse correlations between variables, while the C statistic was used to calculate the diagnostic performance of AMH. AMH levels were significantly correlated with the total number of oocytes retrieved after the DuoStim (R 0.61; CI 0.44–0.70; P < 0.0001). The difference in the total number of oocytes retrieved between the first (median 4 oocytes, interquartile range (IQR) 2–6) and second (median 6 oocytes, IQR 3.2–8) stimulation was statistically significant (P < 0.0001). However, there was no significant difference in the number of mature oocytes that were retrieved (median of 3 and 4 in the first and second stimulations, respectively). After the first stimulation, 68% of patients had at least one blastocyst available, while after the second stimulation, 74% did (NS). Based on linear regression, each 0.25 ng/ml increase in basal AMH corresponds to one additional oocyte recovered at the end of both stimulations (R2: 0.32, P < 0.0001). The results are limited owing to the observational nature of the study and the number of participants. Counselling infertile couples regarding the intermediate outcome of IVF (i.e. number of retrieved oocytes) is one of the most demanding tasks that clinicians face. To our knowledge, this is the first study that provides an easy-to-use clinical tool that enables the quantitative prediction of ovarian response following DuoStim, based on serum AMH values. No external funding was obtained for this study. The authors declare no conflicts of interest. N/A.
- 4 January 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (2) , 315-323
Two clinical case reports of embryonic mosaicism identified with PGT-A persisting during pregnancy as true fetal mosaicism
The health risks associated with transferring embryos classified as mosaic by preimplantation genetic testing for aneuploidies (PGT-A) are currently unknown. Such embryos produce PGT-A results indicating the presence of both euploid and aneuploid cells and have historically been deselected from transfer and grouped with uniformly aneuploid embryos as ‘abnormal’. In recent years, numerous groups have reported the intentional transfer of mosaic embryos in the absence of uniformly euploid embryos, largely observing births of seemingly healthy babies. However, it remains to be understood whether the embryonic mosaicism invariably becomes resolved during the ensuing pregnancy, or whether the placenta and/or fetal tissues retain aneuploid cells, and if so to what potential clinical effect. Here, we report two cases of mosaicism persisting from the embryonic stage to the established pregnancy. Case 1 involved an embryonic low-level segmental mosaic loss in Chromosome (Chr) 1, which was confirmed in amniocentesis as well as in brain tissue of the products of conception. This pregnancy was terminated due to the chromosomal pathologies associated with 1p36 deletion syndrome, such as severe intellectual disability. Case 2 involved a low-level mosaic Chr 21 trisomy, which was confirmed with chorionic villus sampling and amniocentesis. The ensuing pregnancy was terminated after ultrasound identification of severe abnormalities in the placenta and fetus. Together, these two cases should be taken into account for risk-benefit assessments of prospective mosaic embryo transfers.
- 4 January 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (2) , 315-323
Two clinical case reports of embryonic mosaicism identified with PGT-A persisting during pregnancy as true fetal mosaicism
The health risks associated with transferring embryos classified as mosaic by preimplantation genetic testing for aneuploidies (PGT-A) are currently unknown. Such embryos produce PGT-A results indicating the presence of both euploid and aneuploid cells and have historically been deselected from transfer and grouped with uniformly aneuploid embryos as ‘abnormal’. In recent years, numerous groups have reported the intentional transfer of mosaic embryos in the absence of uniformly euploid embryos, largely observing births of seemingly healthy babies. However, it remains to be understood whether the embryonic mosaicism invariably becomes resolved during the ensuing pregnancy, or whether the placenta and/or fetal tissues retain aneuploid cells, and if so to what potential clinical effect. Here, we report two cases of mosaicism persisting from the embryonic stage to the established pregnancy. Case 1 involved an embryonic low-level segmental mosaic loss in Chromosome (Chr) 1, which was confirmed in amniocentesis as well as in brain tissue of the products of conception. This pregnancy was terminated due to the chromosomal pathologies associated with 1p36 deletion syndrome, such as severe intellectual disability. Case 2 involved a low-level mosaic Chr 21 trisomy, which was confirmed with chorionic villus sampling and amniocentesis. The ensuing pregnancy was terminated after ultrasound identification of severe abnormalities in the placenta and fetus. Together, these two cases should be taken into account for risk-benefit assessments of prospective mosaic embryo transfers.
- 25 August 2022
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 37 (10) , 2392-2401
The number and rate of euploid blastocysts in women undergoing IVF/ICSI cycles are strongly dependent on ovarian reserve and female age
Can the possibility of having at least one euploid blastocyst for embryo transfer and the total number of euploid blastocysts be predicted for couples before they enter the IVF programme? Ovarian reserve and female age are the most important predictors of having at least one euploid blastocyst and the total number of euploid blastocysts. The blastocyst euploidy rate among women undergoing ART has already been shown to significantly decrease with increasing female age, and the total number of euploid embryos is dependent on the blastocyst cohort size. However, the vast majority of published studies are based on retrospective analysis of data. This prospective analysis included 847 consecutively enrolled couples approaching their first preimplantation genetic testing for aneuploidies (PGT-A) cycle between 2017 and 2020. Only couples for whom ejaculated sperm was available and women with a BMI of 2 were included in the study. Only the first cycle was included for each patient. The study was conducted at an IVF centre where, for all patients, the planned treatment was to obtain embryos at the blastocyst stage for the PGT-A programme. The impact of the following covariates was investigated: a woman’s serum AMH level, age, height, weight and BMI and a man’s age, height, weight, BMI, sperm volume and sperm motility and morphology. The analysis was performed with a machine learning (ML) approach. Models were fit on the training set (677 patients) and their predictive performance was then evaluated on the test set (170 patients). After ovarian stimulation and oocyte insemination, 40.1% of couples had at least one blastocyst available for the PGT-A. Of 1068 blastocysts analysed, 33.6% were euploid. Two distinct ML models were fit: one for the probability of having at least one euploid blastocyst and one for the number of euploid blastocysts obtained. In the training set of patients, the variable importance plots of both models indicated that AMH and the woman’s age are by far the most important predictors. Specifically, a positive association between the outcome and AMH and a negative association between the outcome and female age appeared. Gradient-boosted modelling offers a greater predictive performance than generalized additive models (GAMs). The study was performed based on data from a single centre. While this provides a robust set of data with a constant ART process and laboratory practice, the model might be suitable only for the evaluated population, which may limit the generalization of the model to other populations. ML models indicate that for couples entering the IVF/PGT-A programme, ovarian reserve, which is known to vary with age, is the most important predictor of having at least one euploid embryo. According to the GAM, the probability of a 30-year-old woman having at least one euploid embryo is 28% or 47% if her AMH level is 1 or 3 ng/ml, respectively; if the woman is 40 years old, this probability is 18% with an AMH of 1 ng/ml and 30% with an AMH of 3 ng/ml. This study was supported by an unrestricted grant from Gedeon Richter. The authors declared no conflict of interests. N/A.
- 25 August 2022
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 37 (10) , 2392-2401
The number and rate of euploid blastocysts in women undergoing IVF/ICSI cycles are strongly dependent on ovarian reserve and female age
Can the possibility of having at least one euploid blastocyst for embryo transfer and the total number of euploid blastocysts be predicted for couples before they enter the IVF programme? Ovarian reserve and female age are the most important predictors of having at least one euploid blastocyst and the total number of euploid blastocysts. The blastocyst euploidy rate among women undergoing ART has already been shown to significantly decrease with increasing female age, and the total number of euploid embryos is dependent on the blastocyst cohort size. However, the vast majority of published studies are based on retrospective analysis of data. This prospective analysis included 847 consecutively enrolled couples approaching their first preimplantation genetic testing for aneuploidies (PGT-A) cycle between 2017 and 2020. Only couples for whom ejaculated sperm was available and women with a BMI of 2 were included in the study. Only the first cycle was included for each patient. The study was conducted at an IVF centre where, for all patients, the planned treatment was to obtain embryos at the blastocyst stage for the PGT-A programme. The impact of the following covariates was investigated: a woman’s serum AMH level, age, height, weight and BMI and a man’s age, height, weight, BMI, sperm volume and sperm motility and morphology. The analysis was performed with a machine learning (ML) approach. Models were fit on the training set (677 patients) and their predictive performance was then evaluated on the test set (170 patients). After ovarian stimulation and oocyte insemination, 40.1% of couples had at least one blastocyst available for the PGT-A. Of 1068 blastocysts analysed, 33.6% were euploid. Two distinct ML models were fit: one for the probability of having at least one euploid blastocyst and one for the number of euploid blastocysts obtained. In the training set of patients, the variable importance plots of both models indicated that AMH and the woman’s age are by far the most important predictors. Specifically, a positive association between the outcome and AMH and a negative association between the outcome and female age appeared. Gradient-boosted modelling offers a greater predictive performance than generalized additive models (GAMs). The study was performed based on data from a single centre. While this provides a robust set of data with a constant ART process and laboratory practice, the model might be suitable only for the evaluated population, which may limit the generalization of the model to other populations. ML models indicate that for couples entering the IVF/PGT-A programme, ovarian reserve, which is known to vary with age, is the most important predictor of having at least one euploid embryo. According to the GAM, the probability of a 30-year-old woman having at least one euploid embryo is 28% or 47% if her AMH level is 1 or 3 ng/ml, respectively; if the woman is 40 years old, this probability is 18% with an AMH of 1 ng/ml and 30% with an AMH of 3 ng/ml. This study was supported by an unrestricted grant from Gedeon Richter. The authors declared no conflict of interests. N/A.
- 7 October 2021
- Published by Elsevier in Fertility and Sterility
- Vol. 116 (5) , 1212-1219
Let the data do the talking: the need to consider mosaicism during embryo selection
- 7 October 2021
- Published by Elsevier in Fertility and Sterility
- Vol. 116 (5) , 1212-1219
Let the data do the talking: the need to consider mosaicism during embryo selection
- 1 July 2021
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 36 (Supplement)
P–091 Magnetic Activated Cell Sorting (MACS) improves euploid blastocysts rate in pre-implantation genetic testing cycles with high levels of sperm DNA fragmentation and advanced paternal age
Study question: Can MACS increase euploid blastocyst rate in Pre-implantation Genetic Testing (PGT) cycles for AMA-APA (Advanced Maternal-Paternal Age) in patients with high sperm DNA fragmentation (SDF)? Summary answer: A slight increase in euploid blastocyst rate was found using MACS in infertile patients with high SDF undergoing PGT cycles compared to the control group. What is known already: Many authors have shown a close correlation between the presence of apoptotic markers on spermatozoa and the failure of assisted reproduction treatments. In normal physiological conditions, apoptotic spermatozoa with phosphatidylserine (PS) residues externalized on the plasma membrane, are eliminated along female genital tract, preventing oocyte fertilization. MACS eliminates apoptotic sperm whit PS residues using superparamagnetic microbeads conjugated with annexin V. This technique reduces the proportion of sperm with high rates of SDF and can be used to maximize ART procedures results. MACS application improves sperm quality, fertilization, cleavage and pregnancy rates reducing miscarriage rate. Study design, size, duration: From June to November 2020, 10 couples in which MACS was applied to select non-apoptotic spermatozoa, were randomly enrolled in our study (MACS group) and 8 couples without MACS were considered as controls (No-MACS Group). All couples in both groups underwent a PGT cycle and had high sperm DNA Fragmentation (> 20%). A higher rate of euploid and diploid-euploid mosaic blastocysts were obtained in the MACS group compared to the control group. Participants/materials, setting, methods: Patients with severe oligoastenoteratozoospermia were excluded. MACS protocol was performed as follows: semen sample was analyzed (WHO 2010) and washed with buffered medium; pellet was removed and a swim-up was performed. Retrieved spermatozoa were washed with a binding buffer (Miltenyi Biotec), centrifuged (400 g x 4 minutes) and supernatant discarded. Pellet was covered with Annexin-V and re-suspended. After 15 minutes incubation at room temperature, the sample was eluted through the column and collected for ICSI. Main results and the role of chance: In MACS group, female and male mean age ± SD were 41.6 ± 2.1 and 43.5 ± 7.3, respectively. Female and male mean age ± SD were 41.7 ± 2.8 and 44.6 ± 8.1 in the No-MACS group, respectively. In MACS and No-MACS groups, injected oocytes were 44 and 35, fertilized oocytes were 32 (72.3%) and 27 (77.1%) (NS), blastocyst formation rates were 71.8% (23/32) and 48.1% (13/27) (NS), respectively. In No-MACS group, only 1 euploid and 1 diploid-euploid mosaic blastocysts were obtained (1/13 = 8%) (NS). In MACS group, 4 euploid blastocysts were formed (4/23 = 17.4%) whereas mosaic diploid-euploid blastocysts were 3/23 (13.0%) (NS). Aneuploid blastocysts were 16/23 (69.6%) in MACS group and 11/13 (84.6%) in No-MACS group (NS). Limitations, reasons for caution: AMA and APA of couples enrolled should be considered as a limit of the study. A larger number of patients and biopsied blastocysts are needed to analyze clinical results and perform a robust statistical analysis establishing if MACS is useful to improve transferable blastocyst rate in patients with high SDF. Wider implications of the findings: MACS is useful to select non apoptotic sperms; although fertilization, cleavage and blastocyst rates are not improved, aneuploid blastocysts rate slightly decreases using MACS. It I possible that, selecting spermatozoa free from PS residues, MACS allows to choose spermatozoa with a better DNA packaging, thus affecting the embryo ploidy. Trial registration number: non applicable
- 1 July 2021
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 36 (Supplement)
P–091 Magnetic Activated Cell Sorting (MACS) improves euploid blastocysts rate in pre-implantation genetic testing cycles with high levels of sperm DNA fragmentation and advanced paternal age
Study question: Can MACS increase euploid blastocyst rate in Pre-implantation Genetic Testing (PGT) cycles for AMA-APA (Advanced Maternal-Paternal Age) in patients with high sperm DNA fragmentation (SDF)? Summary answer: A slight increase in euploid blastocyst rate was found using MACS in infertile patients with high SDF undergoing PGT cycles compared to the control group. What is known already: Many authors have shown a close correlation between the presence of apoptotic markers on spermatozoa and the failure of assisted reproduction treatments. In normal physiological conditions, apoptotic spermatozoa with phosphatidylserine (PS) residues externalized on the plasma membrane, are eliminated along female genital tract, preventing oocyte fertilization. MACS eliminates apoptotic sperm whit PS residues using superparamagnetic microbeads conjugated with annexin V. This technique reduces the proportion of sperm with high rates of SDF and can be used to maximize ART procedures results. MACS application improves sperm quality, fertilization, cleavage and pregnancy rates reducing miscarriage rate. Study design, size, duration: From June to November 2020, 10 couples in which MACS was applied to select non-apoptotic spermatozoa, were randomly enrolled in our study (MACS group) and 8 couples without MACS were considered as controls (No-MACS Group). All couples in both groups underwent a PGT cycle and had high sperm DNA Fragmentation (> 20%). A higher rate of euploid and diploid-euploid mosaic blastocysts were obtained in the MACS group compared to the control group. Participants/materials, setting, methods: Patients with severe oligoastenoteratozoospermia were excluded. MACS protocol was performed as follows: semen sample was analyzed (WHO 2010) and washed with buffered medium; pellet was removed and a swim-up was performed. Retrieved spermatozoa were washed with a binding buffer (Miltenyi Biotec), centrifuged (400 g x 4 minutes) and supernatant discarded. Pellet was covered with Annexin-V and re-suspended. After 15 minutes incubation at room temperature, the sample was eluted through the column and collected for ICSI. Main results and the role of chance: In MACS group, female and male mean age ± SD were 41.6 ± 2.1 and 43.5 ± 7.3, respectively. Female and male mean age ± SD were 41.7 ± 2.8 and 44.6 ± 8.1 in the No-MACS group, respectively. In MACS and No-MACS groups, injected oocytes were 44 and 35, fertilized oocytes were 32 (72.3%) and 27 (77.1%) (NS), blastocyst formation rates were 71.8% (23/32) and 48.1% (13/27) (NS), respectively. In No-MACS group, only 1 euploid and 1 diploid-euploid mosaic blastocysts were obtained (1/13 = 8%) (NS). In MACS group, 4 euploid blastocysts were formed (4/23 = 17.4%) whereas mosaic diploid-euploid blastocysts were 3/23 (13.0%) (NS). Aneuploid blastocysts were 16/23 (69.6%) in MACS group and 11/13 (84.6%) in No-MACS group (NS). Limitations, reasons for caution: AMA and APA of couples enrolled should be considered as a limit of the study. A larger number of patients and biopsied blastocysts are needed to analyze clinical results and perform a robust statistical analysis establishing if MACS is useful to improve transferable blastocyst rate in patients with high SDF. Wider implications of the findings: MACS is useful to select non apoptotic sperms; although fertilization, cleavage and blastocyst rates are not improved, aneuploid blastocysts rate slightly decreases using MACS. It I possible that, selecting spermatozoa free from PS residues, MACS allows to choose spermatozoa with a better DNA packaging, thus affecting the embryo ploidy. Trial registration number: non applicable
- 1 December 2019
- Published by Elsevier in Fertility and Sterility
- Vol. 112 (6) , 1080-1093.e1
Time of morulation and trophectoderm quality are predictors of a live birth after euploid blastocyst transfer: a multicenter study
- 1 December 2019
- Published by Elsevier in Fertility and Sterility
- Vol. 112 (6) , 1080-1093.e1
Time of morulation and trophectoderm quality are predictors of a live birth after euploid blastocyst transfer: a multicenter study
- Top Cited Papers
- 1 January 2018
- Published by Elsevier in Fertility and Sterility
- Vol. 109 (1) , 77-83
Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments
- 1 January 2018
- Published by Elsevier in Fertility and Sterility
- Vol. 109 (1) , 77-83
Top Cited PapersExtent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments